


NCI Acting Director's Report

Douglas R. Lowy, M.D.

6th Joint Virtual Meeting of the Board of Scientific Advisors & National Cancer Advisory Board

June 14, 2022



John Edward Porter Neuroscience Research Center, NIH Building 35A

Congress remembers John E. Porter, appropriator and advocate for NIH

Illinois Republican was a moderate on social programs

Roll Call



“John Porter’s doubling of the NIH budget became a funding priority I sought to emulate during my tenure as Chairman and which I continue to advocate for as ranking member of the panel.”

Rep. Tom Cole (R-OK)



“He was a leader and a voice for principled, bipartisan cooperation within our Illinois congressional delegation.”

Sen. Richard Durbin (D-IL)

Congratulations!

National Cancer Advisory Board

**ASCO-American Cancer Society Cancer
Prevention Award**

Electra D. Paskett, PhD
Ohio State University

**Fellow of the American Society of Clinical
Oncology (FASCO), 2022**

Karen M. Winkfield, MD, PhD
Vanderbilt University

Board of Scientific Advisors

2022 Fellows of the AACR Academy

Jennifer R. Grandis, MD
University of California, San Francisco

Otis W. Brawley, MD, MACP, FASCO, FACE
Johns Hopkins University

NCI Directors: 2010 – Present



**Harold E.
Varmus, M.D.**
2010 – 2015



**Norman E. "Ned"
Sharpless, M.D.**
2017 – 2022



**Douglas R. Lowy,
M.D. (Acting)**
2015 – 2017, 2019,
2022

NCI Leadership Team

James H. Doroshow, MD	Deputy Director	Since 2011
Dinah S. Singer, PhD	Deputy Director	Since 2016
Douglas R. Lowy, MD	Deputy Director	Since 2010
Donna Siegle	Executive Officer/Deputy Director for Management	Since 2016
Eric Cole	Deputy Executive Officer	Since 2019
Patrick McGarey, JD	Associate Director for Finance and Legislation	Since 2015
Anne Lubenow	Chief of Staff, previously Deputy Executive Officer	Since 2019/2011
Maureen Johnson, PhD	Special Assistant to the Director	Since 2006

Some Key NCI Initiatives and Decisions 2015 - 2019



2015 **Precision Medicine Initiative-Oncology**



2015 **National Cryo-EM user facility** at Frederick National Laboratory



2016 **Cancer Moonshot** (21st Century Cures Act)



2016-2022 **>\$40M increase to P30 support grants for NCI-designated cancer centers**



2019 Enabled Congress to recognize low NCI funding rates for **investigator-initiated research**

Some Current and Near-Future NCI Activities

CANCER GRAND CHALLENGES	CANCER MOONSHOT	CANCER CENTERS	FREDERICK NATIONAL LAB
<ul style="list-style-type: none">• With Cancer Research UK• First awards to be announced this week• Participate in development and process for next round	<ul style="list-style-type: none">• Continue to fund the most promising initiatives of the initial Cancer Moonshot: a “soft landing”• Year of planning for next phase	<ul style="list-style-type: none">• Develop Phase 3 for the P30 Cancer Center Support Grants	<ul style="list-style-type: none">• Select at least one new signature project at Frederick National Lab

Some Major Meetings and Events (Recent & Upcoming)

- American Association for Cancer Research (AACR) Remarks and Fireside Chat with Dr. David Tuveson, informal press “gaggle”– *April 2022*
- National Association of Cancer Center Development Officers (NACCDO)-Public Affairs and Marketing Network (PAMN) – *April 2022*
- ASCO Plenary Speech and Meeting with Board of Directors – *June 3-4, 2022*
- Meeting with AACI – *October 2022*



FY 2023 Budget Request for the National Institutes of Health

House Committee on Appropriations Hearing, May 11, 2022




“This [2022 omnibus] includes an increase of \$353 million to fund a greater number of research proposals at the NCI and support for the Cancer Moonshot initiative **that will save lives by speeding cancer research progress and improving prevention detection and treatment efforts.**”

–Chair Rosa DeLauro (D-CT)

“Cancer research... is something I think our investments with you all [NCI] are proving to be great... **the research is just truly incredible, as are the results.** So, keep up the good fight.”

–Representative Chuck Fleischmann (R-TN)

President's NCI Budget and Enacted Appropriations



- Strong bipartisan support for cancer research across Congress
- Congress has declined to cut funding to cancer research – even in challenging budget cycles

Recent online conversation about health equity

 NATIONAL CANCER INSTITUTE

Equity in
the Healthcare
Workforce:
Why it Matters
for Patients

Wednesday, June 8, 2022
3:15 p.m. ET

  Live across NCI's Facebook and YouTube Accounts

PARTICIPANTS

Dr. Doug Lowy
National Cancer Institute Acting Director

Dr. Paulette Gray
National Cancer Institute

Dr. Jeffrey Hall
Centers for Disease Control and Prevention

Dr. Randy Jones
Oncology Nursing Society




youtube.com/NCIgov
facebook.com/cancer.gov



“What [achieving workforce diversity and equity] potentially means is that the way we provide care, the way that we deliver services, is really going to more effectively account for things such as the economic, environmental, social, as well as political conditions that shape health.”

- Dr. Jeffrey Hall

Age-adjusted cancer mortality trends by race and ethnicity (2000-19)




Source: NCI Surveillance, Epidemiology, and End Results Program (SEER), seer.cancer.gov



For more, see Lawrence, et al: **Trends in Cancer Mortality Among Black Individuals in the U.S. From 1999 to 2019** – *JAMA Oncology*, May 19, 2022

Increasing rate of FDA approvals: lung cancer treatment



Source: Lung Cancer Research Foundation



See also Howlader, et al: **The Effect of Advances in Lung-Cancer Treatment on Population Mortality** - *New England Journal of Medicine*, Aug 13, 2020

Advances in treating *KRAS* mutants in people with cancer

Numbers of new cancer cases per year in the U.S. that contain the most frequent *KRAS* mutant alleles


	All <i>KRAS</i>	G12C	G12D
Lung	45,600	23,000	9,200
Pancreas	32,200	1,000	19,500
Colorectal	60,000	5,700	25,000
Total new cases per year	137,800	29,700	53,700

NCI-Frederick: Patient-derived Models Repository

<https://pdmr.cancer.gov>

Specifically targeting mutant *KRAS*:

- **G12C inhibitor** *FDA-approved May 28, 2021*
- **G12D inhibitor** *clinical trials soon*



Ostram, et al, Nature 2013

Uterine Cancer Death Rates Rising, Highest Among Black Women in the United States

- **Black women are 2x as likely to die of uterine cancer** compared to other racial and ethnic groups.
- Most of the mortality increase is attributable to non-endometrioid uterine cancer, **which disproportionately affects Black and Hispanic women.**
- Non-endometrioid cancer mortality **increased 3.5% per year for Black women and 6.7% for Hispanic women** between 2010 and 2017.





- **There is an urgent need for new research in the affected populations.**




Clarke, et al. **Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype.** *JAMA Oncology.* May 5, 2022

ANCHOR Trial Results: Treatment of high-grade anal epithelial dysplasia reduces risk of progression to invasive anal cancer (HIV-positive patients)



Palefsky, et al., 2022



Coming soon: Palefsky, et al. **Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.** *New England Journal of Medicine.* June 16, 2022

Cancer MoonshotSM: Accelerate discovery, increase collaboration, and expand data sharing

In the Cancer Moonshot's first 4 years (2017-2021)



**>2,000
Publications**




**49
Clinical
Trials**



**>30
Patent
Filings**

Cancer Moonshot Funding Authorized Under the 21st Century Cures Act (dollars in millions)



We should continue to support the most promising initiatives from the initial Cancer Moonshot while developing additional activities to meet challenging new goals.

Goals of Cancer Moonshot Next Phase

- 1 Cut the cancer death rate in half within 25 years.
- 2 Transform the meaning of cancer.
- 3 Address cancer-associated inequities.


Accomplishing the New Goals




Invest in the pipeline of new drugs for cancer prevention, interception, and treatment



Ensure equitable health care delivery of current and new standards of care



Expand clinical trials to speed evaluation of candidate interventions in diverse populations (racial, ethnic, geographic)



Increase diversity of cancer research and care workforce to resemble the communities we serve

Some FY 23 Activities to Support Ongoing Moonshot and Jumpstart Next Phase

TOMORROW

Proposed Funding Opportunity Announcements (FOAs)

- Cancer Moonshot Scholars Diversity Program
- Feasibility Trial for Asymptomatic Multi-Cancer Detection Screening



Notices of Special Interest, Request for Information

- Adapt Visualization Methods to Enhance Cancer Moonshot Data
- Harmonize Existing Data to Human Tumor Atlas Network (HTAN) Standards
- Fusion Oncoproteins in Childhood Cancers

View details at cancer.gov/moonshot.

Thank you!

www.cancer.gov

www.cancer.gov/espanol

1-800-4-CANCER

NCInfo@nih.gov

[@NCIDirector](#)

[@TheNCI](#)



NATIONAL
CANCER
INSTITUTE